Regenics shareholders as of December 15th  2017.

(minor deviations within source documents due to rounding of integers may apply)  

 

 

SHARES

%

Collas AS

189.500

3,1

Runhild Gammelsæter

94.200

1,6

Camilla Haglerød

22.000

0,4

Rune Nilsen

100.000

1,7

Life Capitol AS

2.063.300

34,1

Greyston Holding AS

117.700

2,0

Capra Invest AS

160.800

2,7

e-invest AS

117.300

1,9

Heldrup AS

1.831.200

30,3

Marcus Heldrup

100.800

1,7

Cornucopia AS

628.800

10,4

Intento AS

432.800

7,2

Gry Lønne Eriksson

65.000

1,1

 WLH Invest AS

 71.429

1,2

 Solvik Holding AS

 29.143

0,5

 Bent Eriksen AS

 14.579

0,2

 Siesta Invest AS

 14.578

0,2

SUM

6.047.929

100,00

 

Collas AS : Philippe Collas, Founder and Scientific Advisor

Runhild Gammelsæter: former CEO, private

Camilla Haglerød: former CEO, private

Rune Nilsen: private

Life Capitol AS: Jan Remmereit, founder

Greystone Holding AS: Jan Remmereit, founder

Heldrup AS: Tore Heldrup Rasmussen, Chairman Board

Markus Heldrup: Head of production, CPO, employee

Cornucopia AS: Henrik Lund, CEO, consultant

Intento AS: Christian Clemm, CMO, employee

Gry Lønne Eriksson:  Gry Lønne Eriksson, CSO, employee

WLH Invest AS: private

Solvik Holding AS: private

Bent Eriksen AS: private

 Siesta Invest AS: private

 

Planned/completed share issues:

2015: Gross proceeds 1.0 mill NOK 

2016: Gross proceeds 1.72 mill NOK

2017: Gross proceeds 1.0 mill NOK (August)

2017: Gross proceeds 2.25 mill NOK (December), supported by Forum Securities AS

Protocols (password required):

Annual Meeting 2015

Annual Meeting 2016

Ex. Ord. Annual Meeting 2016

Annual Meeting 2017

Ex. Ord. Annual Meeting 2017

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.